Carolina Mosoni studies alcohol use disorder, particularly among vulnerable populations like homeless individuals and patients with liver disease. She looks at how various treatments, including medications like baclofen, can help reduce alcohol consumption and improve quality of life. Additionally, her research examines the gut bacteria of patients with AUD, revealing how these microorganisms can influence health outcomes. By investigating conditions related to alcohol use, such as Madelung's disease, she seeks to enhance diagnosis and treatment options for these patients.
Key findings
In a treatment study, patients' average alcohol consumption dropped from 10 drinks a day to 2 after six months and to 0 after one year.
Patients with alcohol use disorder showed a 93.4% accuracy in identifying specific changes in gut bacteria compared to healthy individuals.
Baclofen significantly helped reduce alcohol consumption in patients with liver cirrhosis, showcasing its safety and effectiveness in this population.
Frequently asked questions
Does Dr. Mosoni study alcohol use disorder?
Yes, she focuses on various aspects of alcohol use disorder, including treatment methods and its effects on health.
What treatments has Dr. Mosoni researched for alcohol use disorder?
She has researched the use of baclofen, a medication that effectively reduces alcohol consumption in patients with liver cirrhosis.
Is Dr. Mosoni's work relevant to patients with liver disease?
Absolutely, her research specifically examines the interaction between alcohol use disorder and liver health, providing valuable insights for these patients.
Publications in plain English
Enhancing critical raw materials recovery in micro e-mobility: Regulatory strategies for the EU.
2026
Waste management & research : the journal of the International Solid Wastes and Public Cleansing Association, ISWA
Turunen T, Mosoni C, Kautto P
Plain English This study looked at how to improve the recycling of important materials found in e-bikes and e-scooters, which are becoming more popular in Europe. The researchers found that current EU rules do not do enough to encourage the recovery of these materials, which are essential for making new devices. To fix this, they suggest setting clear recycling goals and requiring that new electronic products contain a certain amount of recycled materials.
Who this helps: This benefits manufacturers and environmental policymakers working to make e-mobility more sustainable.
Long term anticoagulation for Catheter-Related deep vein thrombosis of the upper extremities in women with cancer: retrospective analysis of effectiveness and safety outcomes.
2025
Journal of thrombosis and thrombolysis
Cavallaro C, Santini P, Leoni L, Mosoni C, D'Ambrosio S +7 more
Plain English This study looked at how effective and safe different lengths of blood-thinning treatment are for women with cancer who develop clots related to their central venous catheters. Researchers analyzed data from 113 women, finding that the chance of blood clots returning was very low at 0.5% per year, while major bleeding events occurred at a rate of 1.9%. Additionally, most patients showed significant improvement in their blood clots over a year, with 87.3% fully resolving after 12 months.
Who this helps: This helps women with cancer who are at risk of developing blood clots from treatment.
Assuming accuracy, pretending influence? Risks of measuring, monitoring and reporting sustainable development goals.
2023
Ambio
Lyytimäki J, Eckert N, Lepenies R, Mosoni C, Mustajoki J +1 more
Plain English This study looked at the risks involved in tracking and reporting on sustainable development goals (SDGs) as part of global efforts to improve conditions for people and the planet. Researchers found that while some data issues are well recognized, such as the availability of information, there are also overlooked problems like the tendency to report without critically assessing the SDGs' effectiveness. Addressing these risks is crucial to ensure that sustainability efforts genuinely lead to meaningful progress.
Who this helps: This helps policymakers and organizations involved in sustainability efforts.
Sustainable Development Goals and risks: The Yin and the Yang of the paths towards sustainability.
2023
Ambio
Eckert N, Rusch G, Lyytimäki J, Lepenies R, Giacona F +7 more
Plain English This study looked at how the United Nations' Sustainable Development Goals (SDGs) relate to risks that come up when trying to achieve a sustainable future. Researchers found that by redefining how we think about risks in broader, more interconnected ways, we can reduce risks and support socio-environmental systems better, showing that SDGs and risks are tightly linked. This matters because understanding this relationship can help improve our approach to sustainability and risk management.
Who this helps: This benefits communities, policymakers, and environmental organizations looking to implement effective sustainability strategies.
Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement.
2023
Cancers
Cerrito L, Mignini I, Ainora ME, Mosoni C, Gasbarrini A +1 more
Plain English This study examined how measuring liver stiffness can help assess the risk of liver cancer (hepatocellular carcinoma or HCC) in patients with nonalcoholic fatty liver disease (NAFLD). The review of recent data found that techniques like ultrasound and magnetic resonance elastography can effectively evaluate liver stiffness and are now recommended for checking liver health in these patients. This is important because it helps identify individuals at higher risk for liver cancer, leading to better monitoring and treatment strategies.
Who this helps: This benefits patients with nonalcoholic fatty liver disease.
The politics of national SDG indicator systems: A comparison of four European countries.
2023
Ambio
Lepenies R, Büttner L, Bärlund I, Jax K, Lyytimäki J +6 more
Plain English This research looked at how four European countries are tracking progress on sustainable development goals (SDGs) set by the United Nations. The study found that these countries have created different systems to choose and manage their sustainability indicators, with significant variations in how they define and approach sustainability among them. For example, the level of public participation and the way governments communicate about indicators differ widely, impacting overall effectiveness.
Who this helps: This benefits policymakers and governments looking to improve their sustainability efforts and frameworks.
Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients.
2023
Journal of clinical medicine
Santini P, Mosoni C, D'Errico A, Porceddu E, Lupascu A +4 more
Plain English Researchers studied the use of a low dose of the blood thinner rivaroxaban to prevent blood clots in cancer patients who have already received treatment for a previous clot. They found that only 3.8% of patients experienced a recurrence of blood clots after taking rivaroxaban at a dose of 10 mg daily for about 11 months, with no major bleeding incidents reported. This is important because it provides a possible way to safely reduce the risk of more blood clots in cancer patients, a group that often struggles with this issue.
Who this helps: This benefits cancer patients at risk of developing blood clots.
Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy.
2022
Cancers
Cerrito L, Ainora ME, Mosoni C, Borriello R, Gasbarrini A +1 more
Plain English This study looked at how well certain tests, known as biomarkers, can predict how effective treatments will be for advanced liver cancer (hepatocellular carcinoma, or HCC). The researchers found that while imaging tests are currently the most common tools for diagnosing and monitoring HCC, only alpha-fetoprotein (AFP) is widely used for tracking the disease's progress, with other markers largely having little clinical impact. This matters because finding better biomarkers could improve treatment outcomes and potentially lower healthcare costs.
Who this helps: This information benefits doctors and patients dealing with advanced liver cancer.
Pulmonary Embolism in COVID-19 Patients: Which Diagnostic Algorithm Should We Use?
2021
Frontiers in cardiovascular medicine
Porfidia A, Mosoni C, Talerico R, Porceddu E, Lupascu A +3 more
Plain English This study looked at how to best diagnose pulmonary embolism (a blockage in the lungs) in COVID-19 patients who were struggling to breathe. Researchers found that out of 93 patients, 73 (about 78%) should have had a specific scan called a CT pulmonary angiography (CTPA) to check for this condition, but only 28 (about 30%) actually got the scan. Among those who were scanned, 10 had pulmonary embolism, highlighting that the condition is common but many patients aren't being properly tested.
Who this helps: This research helps doctors by providing clearer guidelines for diagnosing pulmonary embolism in COVID-19 patients.
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease.
2020
Liver international : official journal of the International Association for the Study of the Liver
Addolorato G, Ponziani FR, Dionisi T, Mosoni C, Vassallo GA +14 more
Plain English This study looked at the gut bacteria of 36 patients with alcohol use disorder (AUD) and liver disease, comparing them to 36 healthy individuals. Researchers found that patients with AUD had less diverse gut bacteria and specific changes in their gut microbes that could identify them with 93.4% accuracy. Additionally, levels of harmful substances and inflammatory markers were significantly higher in AUD patients, especially in those with severe liver disease.
Who this helps: This research benefits patients with alcohol use disorder and their healthcare providers by providing insights into how gut bacteria may influence liver health.
Make Mission Impossible Feasible: The Experience of a Multidisciplinary Team Providing Treatment for Alcohol Use Disorder to Homeless Individuals.
2020
Alcohol and alcoholism (Oxford, Oxfordshire)
Dionisi T, Mosoni C, Di Sario G, Tarli C, Antonelli M +11 more
Plain English This study looked at how a team of health professionals helped homeless individuals with alcohol use disorder (AUD) by providing a short inpatient treatment and ongoing support. The results showed that after six months, alcohol consumption dropped from an average of 10 drinks a day to just 2, and after a year, the average fell to 0 drinks. Improving treatment and supporting these individuals as they find stable housing can lead to better recovery outcomes.
Who this helps: This helps homeless individuals struggling with alcohol use disorder.
Madelung's disease and acute alcoholic hepatitis: case report and review of literature.
2019
European review for medical and pharmacological sciences
Vassallo GA, Mirijello A, Tarli C, Rando MM, Antonelli M +9 more
Plain English This study looked at Madelung's disease, a rare condition where fatty tumors grow symmetrically around the neck and shoulders, often in men who have abused alcohol. The researchers also shared a case of a man who had both Madelung's disease and severe liver inflammation due to alcohol use. Understanding this link is important for better diagnosis and treatment of patients facing these issues.
Who this helps: This helps patients suffering from Madelung's disease and their doctors.
Alcohol addiction - the safety of available approved treatment options.
2018
Expert opinion on drug safety
Antonelli M, Ferrulli A, Sestito L, Vassallo GA, Tarli C +5 more
Plain English This study looked at the safety of various approved medications for treating alcohol addiction, including disulfiram, naltrexone, acamprosate, nalmefene, sodium oxybate, and baclofen. The researchers found that while all these treatments can be useful for patients with alcohol use disorders who do not have severe liver disease, baclofen is the only medication that has been tested and shown to be safe for patients with advanced liver disease. This is significant because understanding the safety of these medications helps doctors prescribe the right treatment for patients based on their health conditions.
Who this helps: Patients with alcohol use disorders, especially those with liver issues.
Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study.
2018
Alcohol and alcoholism (Oxford, Oxfordshire)
Vassallo GA, Tarli C, Rando MM, Mosoni C, Mirijello A +10 more
Plain English This study looked at liver transplant outcomes for patients with alcoholic liver disease (ALD) compared to those with viral liver disease. Researchers found that survival rates were similar for both groups, but patients with ALD had a higher occurrence of cancer after their transplant, and cancer was the main cause of death in these patients. This matters because it highlights the need for regular cancer screenings and smoking cessation support for patients who have undergone transplantation for alcoholic cirrhosis.
Who this helps: This helps patients with alcoholic liver disease, their doctors, and healthcare providers managing their care.
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats.
2018
Alcoholism, clinical and experimental research
Posteraro B, Paroni Sterbini F, Petito V, Rocca S, Cubeddu T +13 more
Plain English This study looked at how heavy drinking affects gut bacteria and liver health in alcohol-preferring rats. After 12 months of drinking, the rats developed liver fat accumulation and higher levels of toxins in their blood, while their gut bacteria significantly changed, with certain types becoming more abundant. Understanding these relationships is important because it can help us find better ways to prevent and treat diseases related to alcohol consumption.
Who this helps: This helps patients struggling with alcohol use and healthcare providers treating alcohol-related conditions.
Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence.
2018
Frontiers in psychiatry
Mosoni C, Dionisi T, Vassallo GA, Mirijello A, Tarli C +7 more
Plain English This research focused on the use of baclofen, a medication, to treat people with Alcohol Use Disorder (AUD) who also have severe liver disease (cirrhosis). It found that baclofen effectively helped reduce alcohol consumption and encouraged patients to stop drinking, all while being safe for those with liver issues. This is important because traditional treatments often don't work well for these patients, and effective options are needed to improve their health and quality of life.
Who this helps: This helps patients with Alcohol Use Disorder and liver cirrhosis.
Dental health in patients affected by alcohol use disorders: a cross-sectional study.
2017
European review for medical and pharmacological sciences
Manicone PF, Tarli C, Mirijello A, Raffaelli L, Vassallo GA +9 more
Plain English This study looked at how long-term alcohol abuse affects dental health. Researchers compared 23 patients with alcohol use disorders to 23 healthy social drinkers and found that the patients with alcohol problems had worse oral hygiene and higher rates of dental issues. Specifically, alcohol users had more decayed, missing, or filled teeth and poorer scores for plaque and periodontal health. This is important because it highlights that chronic alcohol abuse can lead to serious oral health problems, especially when combined with smoking.
Who this helps: This information is valuable for patients struggling with alcohol use, their doctors, and dental health professionals.